Pathological complete response following systemic therapy with carboplatin-paclitaxel plus pembrolizumab for initially unresectable mismatch repair-deficient advanced endometrial cancer: two case reports

This study investigates the effectiveness of carboplatin-paclitaxel combined with pembrolizumab in achieving a pathological complete response (pCR) in patients with initially unresectable mismatch repair-deficient (dMMR) advanced endometrial cancer. The authors present two case reports where patients achieved pCR following this systemic therapy, suggesting that this treatment approach may allow for less invasive surgical options. The findings highlight the potential of chemo-immunotherapy to improve treatment outcomes in advanced dMMR endometrial cancer.